Polycystic ovary syndrome and hyperprolactinemia are distinct entities

Gynecological Endocrinology

Volumn 23, Issue 5, 2007, Pages 267-272

  Filho, Roberpaulo Barboza ^a   Domingues, Lucilia ^b   Naves, Luciana ^b   Ferraz, Elenice ^b   Alves, Adriana ^b   Casulari, Luiz Augusto ^b,c  

^a Endocrinology and Neurology Clinics CLINEN   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c CLINEN Ed América Office Tower ^*  (Brazil)

Author keywords

Hyperprolactinemia; Insulin resistance; Macroprolactinemia; Ovary; Polycystic ovary syndrome

Indexed keywords

BUSPIRONE; CABERGOLINE; INSULIN; ORAL CONTRACEPTIVE AGENT; PROLACTIN; TIANEPTINE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; STATISTICAL ANALYSIS;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERPROLACTINEMIA; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; PROLACTIN; RETROSPECTIVE STUDIES;

EID: 34250183785     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701297708     Document Type: Article

References (61)

1. Slowey MJ. Polycystic ovary syndrome: new perspective on an old problem. South Med J 2001;94:190-196.
2. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899.
3. Sharma A, Atiomo W. Recent developments in polycystic ovary syndrome. Curr Obstet Gynaecol 2003;13:281-286.
4. Panidis DK, Rousso DH, Matalliotakis IM, Kourtis AI, Vlassis GD, Koumantakis EE. Hyperinsulinemia does not influence androgens/estrogens ratio in patients with polycystic ovary syndrome. Int Fertil Womens Med 1999;44:301-306.
5. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90:3236-3242.
6. Yen SSC. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980;12:207-208.
7. Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987;1:235-245.
8. Franks S. Polycystic ovary syndrome. N Eng J Med 1995;333:853-861.
9. Motta LDC, Motta LACR. Síndrome dos ovários policísticos. J Bras Ginecol 1999;109:3-8.
10. Motta LDC, Motta LACR. Síndrome dos ovários policísticos: fisiopatologia e tratamento. Brasilia Med 2000;37:31-37.
11. Buvat J, Herbaut MB, Marcolin G, Racadot A, Fourlinnie JC, Beuscart R, Fossati P. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome. J Clin Endocrinol Metab 1986;63:119-124.
12. Parsanezhad ME, Alborzi S, Jahromi BN. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Int J Fertil Womens Med 2002;47:272-277.
13. Zacur HA, Foster GV. Hyperprolactinemia and polycystic ovary syndrome. Semin Reprod Endocrinol 1992;10:236-242.
14. Leblanc H, Lachelin GC, Abu-Fadil S, Yen SSC. Effect of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab 1976;43:668-735.
15. Quigley ME, Rakoff JS, Yen SSC. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab 1981;52:231-234.
16. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 1989;31:87-120.
17. Barnes RB, Lobo RA. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J Clin Endocrinol Metab 1985;61:779-782.
18. Steingold KA, Lobo RA, Judd HL. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 1986;62:1048-1051.
19. Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res 2004;62:283-287.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and cell b function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
21. Venturoli S, Porcu E, Fabbri R, Magrini O, Paradisi R, Pallotti G, Gammi L, Flamigni C. Postmenarchal evolution of endocrine pattern and ovarian aspect in adolescents with menstrual irregularities. Fertil Steril 1987;48:78-85.
22. Szilagyi A, Hole R, Keckstein J, Rossmanith WG. Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease. Gynecol Endocrinol 1993;7:159-166.
23. Laatikainen T, Tulenheimo A. Prolactin pulsatility in polycystic ovarian disease. J Endocrinol Invest 1985;8:157-161.
24. Murdoch AP, Dunlop W, Kendall-Taylor P. Studies of prolactin in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1986;24:175.
25. Bahceci M, Tuzcu A, Baheci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 2003;26:655-659.
26. Lunde O. Hyperprolactinemia in polycystic ovary syndrome. Ann Chir Gynaecol 1981;70:197-201.
27. Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril 1984;41:719-725.
28. Carmina E, Rosato F, Maggiore M, Gagliano AM, Indovina D, Janni A. Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern. Acta Endocrinol (Copenh) 1984;105:99-104.
29. Wortsman J, Hirschowitz JS. Galactorrhoea and hyperprolactinemia during treatment of polycystic ovary syndrome. Obstet Gynecol 1980;55:460-463.
30. Duignan NM. Polycystic ovarian disease. Br J Obstet Gynaecol 1976;83:593-602.
31. Buvat J, Siame-Mourot C, Fourlinnie JC, Lamaire A, Buvat-Herbaut M, Hermand E. Androgens and prolactin levels in hirsute women with either polycystic ovaries or 'borderline ovaries'. Fertil Steril 1982;38:695-700.
32. Peillon F, Vincens M, Cesselin F, Doumith R, Mowszowicz I. Anovulatory cycles with an apparently normal level of blood prolactin. Treatment by bromocriptine. Nouv Presse Med 1979;8:3269-3270.
33. Alger M, Velasquez-Matute L, Mason M, Canales ES, Zarate A. Polycystic ovarian disease associated with hyperprolactinemia and defective response. Fertil Steril 1980;34:70-71.
34. Corenblum B, Taylor PJ. A rationale for the use of bromocriptine in patients with amenorrhea and normoprolactinemia. Fertil Steril 1980;34:239-241.
35. Corenblum B, Taylor PJ. The hyperprolactinemic polycystic ovary syndrome may not be a distinct entity. Fertil Steril 1982;38:549-552.
36. Buvat J, Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie JC, Fossati P. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome. Fertil Steril 1985;44:356-360.
37. Shoupe D, Lobo RA. Prolactin response after gonadotropin-releasing hormone in the polycystic ovary syndrome. Fertil Steril 1985;43:549-553.
38. Falaschi P, Del Pozo E, Rocco A, Toscano V, Petrangeli E, Pompei P, Frajese G. Prolactin release in polycystic ovary. Obstet Gynecol 1980;55:579-582.
39. Seppala M, Hirvonen E. Raised serum prolactin levels associated with hirsutism and amenorrhoea. Br Med J 1975;4:144-145.
40. Hamori M, Szendei G, Kovacs I, Somos P. The connection between hyperprolactinemia and polycystic ovary syndrome. Zentralbl Gynakol 1987;109:481-486.
41. Franks S, Murray MAF, Jequier AM, Steele SJ, Nabarro JD, Jacobs HS. Incidence and significance of hyperprolactinemia in women with amenorrhoea. Clin Endocrinol (Oxf) 1975;4:597-607.
42. Paoletti AM, Cagnacci A, Soldani R, Orru M, Ajossa S, Pittorra G, Mulas P, Melis GB. Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Fertil Steril 1995;64:1094-1098.
43. Vilar L, Naves LA, Casulari LA. Hiperprolactinemia - problemas no diagnóstico. Brasilia Med 2005;42:1-7.
44. Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemia patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003;49:1504-1509.
45. Escobar-Morreale HF. Macroprolactinemia in women presenting with hyperandrogenic symptoms: implications for the management of polycystic ovary syndrome. Fertil Steril 2004;82:1697-1699.
46. Forbes AP, Henneman PH, Griswold GC, Albright F. Syndrome characterized by galactorrhea, amenorrhea, and low urinary FSH: comparison with acromegaly and normal lactation. J Clin Endocrinol Metab 1954;14:265-271.
47. Lavric MC. Galactorrhea and amenorrhea with polycystic ovaries. Del Castillo syndrome or polycystic ovarian disease. Am J Obstet Gynecol 1969;104:814-817.
48. Thorner MO, McNeilly AS, Hagan C, Besser GM. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J 1974;2:419-422.
49. Barnes RB, Mileikowsky GN, Cha KY, Spencer CA, Lobo RA. Effects of dopamine and metoclopramide in polycystic ovary syndrome. J Clin Endocrinol Metab 1986;63:506-509.
50. Motta LDC, Motta LACR, Gagliardi ART. Bromocriptina na síndrome dos ovários policísticos: uma revisão. J Bras Ginecol 1989;99:177-181.
51. Crosignani PG, Reschini E, Lombroso GC, Arosio M, Peracchi M. Comparison of placebo and bromocriptine in the treatment of patients with normoprolactinaemic amenorrhoea. Br J Obstet Gynaecol 1978;85:773-75.
52. McBain JC, Popperell RJ. Use of bromocriptine in unexplained infertility. Clin Reprod Fertil 1982;1:145-150.
53. Coelingh Bennink HJ, van der Steeg HJ. Failure of bromocriptine to restore the menstrual cycle in normoprolactinemic post-pill amenorrhea. Fertil Steril 1983;39:238-240.
54. Murdoch AP, McClean KG, Watson MJ, Dunlop W, Kendall Taylor P. Treatment of hirsutism in polycystic ovary syndrome with bromocriptine. Br J Obstet Gynaecol 1987;94:358-365.
55. El Tabakh GH, Loutli A, Azab I, Rahman HA, Aleem FA, Southren AL. A controlled clinical trial for the effect of bromocriptine on the adrenal contribution in polycystic ovary syndrome. Acta Endocrinol (Copenh) 1987;114:161-165.
56. Spruce BA, Taylor PK, Dunlop W, Anderson AJ, Watson MJ, Cook DB, Gray C. The effect of bromocriptine in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1984;20:481-488.
57. Dewailly D, Buvat J, Fourlinnie JC, Fessati P, Linquette M. Effects cliniques et biologiques de ládministracion prolongée de bromocriptine dans la maladie des ovaries polykystiques. Ann Endocrinol (Paris) 1982;43:134.
58. Thorner MO, Besser GM, Jones A, Dacie J, Jones AE. Bromocriptine treatment of female infertility: report of 13 pregnancies. Br Med J 1975;4:694-697.
59. Ito M, Matsuura K, Aiko A, Matsui K, Yoshimura T, Okamura H. Successful treatment with bromocriptine of hypertension associated with polycystic ovarian disease. Acta Obstet Gynecol Scand 1987;66:279-282.
60. Blum I, Bruhis S, Kaufman H. Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. Fertil Steril 1981;35:629-633.
61. Blum I, Kaufman H, Merilus R, Rusecki Y, Chovers I. Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. Obstet Gynecol 1981;57:661-665.